Zengtian X. Sun

84 West Huaihai Road
Xuzhou, 221002, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

BCMA/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares.

BCMA/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares.

Journal: Science advances

Published: January 02, 2026

High FCRL5 expression predicts poor treatment response and survival in newly diagnosed multiple myeloma: a retrospective study.

High FCRL5 expression predicts poor treatment response and survival in newly diagnosed multiple myeloma: a retrospective study.

Journal: Frontiers in oncology

Published: December 10, 2025

Progress in metabolomics of multiple myeloma

Progress in metabolomics of multiple myeloma

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: December 03, 2025

BCR::ABL1-Positive Secondary B-Acute Lymphoblastic Leukemia Mimicking Acute Megakaryoblastic Leukemia Following Multiple Myeloma

BCR::ABL1-Positive Secondary B-Acute Lymphoblastic Leukemia Mimicking Acute Megakaryoblastic Leukemia Following Multiple Myeloma

Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology

Published: August 27, 2025

Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma.

Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma.

Journal: Blood

Published: August 19, 2024

MTH1 protects platelet mitochondria from oxidative damage and regulates platelet function and thrombosis.

MTH1 protects platelet mitochondria from oxidative damage and regulates platelet function and thrombosis.

Journal: Nature communications

Published: January 29, 2023

The STAT3 inhibitor stattic overcome bortezomib-resistance in multiple myeloma via decreasing PSMB6.

The STAT3 inhibitor stattic overcome bortezomib-resistance in multiple myeloma via decreasing PSMB6.

Journal: Experimental cell research

Published: December 31, 2022

Impaired Platelet Function and Thrombus Formation in PDE5A-Deficient Mice.

Impaired Platelet Function and Thrombus Formation in PDE5A-Deficient Mice.

Journal: Thrombosis and haemostasis

Published: October 17, 2022

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma.

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma.

Journal: Frontiers in immunology

Published: August 15, 2022

Protein tyrosine phosphatase PTPN22 negatively modulates platelet function and thrombus formation.

Protein tyrosine phosphatase PTPN22 negatively modulates platelet function and thrombus formation.

Journal: Blood

Published: January 14, 2022

Inhibition of IL-1 Receptor-Associated Kinase 1 Decreases Murine Acute Graft-versus-Host Disease While Preserving the Graft-versus-Lymphoma Effect.

Inhibition of IL-1 Receptor-Associated Kinase 1 Decreases Murine Acute Graft-versus-Host Disease While Preserving the Graft-versus-Lymphoma Effect.

Journal: Transplantation and cellular therapy

Published: July 05, 2021

Myelomatous pleural effusion treated with daratumumab and intrapleural bortezomib: a case report

Myelomatous pleural effusion treated with daratumumab and intrapleural bortezomib: a case report

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: May 13, 2021

Showing 1-12 of 20

Last Updated: 09/26/2026